Denali Therapeutics Inc.
DNLICIK 0001714899 · Biological Products, (No Diagnostic Substances) · Nasdaq
Revenue (TTM)
$1.27M
Q1 May 2026
Net Income (TTM)
−$512.44M
−21.2% YoY
Q1 May 2026
EPS Diluted (TTM)
−$2.93
−15.6% YoY
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-43,830.6%
Q1 May 2026
Net Margin
-40,445.0%
Q1 May 2026
Free Cash Flow (TTM)
−$447.57M
Q1 May 2026
Cash
$387.63M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
158.71M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
Balance Sheet
Cash vs Debt
Latest news
All news →-
High Positive
Denali Therapeutics (DNLI) Sells Priority Review Voucher for $195M
Denali Therapeutics will receive $195 million in gross proceeds from the sale of a rare pediatric disease priority review voucher awarded after the FDA approved...